Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-18T22:19:41.844Z Has data issue: false hasContentIssue false

Dysphagia in the neuroleptic malignant syndrome

Published online by Cambridge University Press:  02 January 2018

J. Shamash
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
L. Miall
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
F. Williams
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
D. Creamer
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
S. Robinson
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
D. G. Johnston
Affiliation:
Department of Metabolic Medicine and Metabolism, St. Mary's Hospital, Praed Street, London W2 1NY
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1994 The Royal College of Psychiatrists 

References

Bristow, M. F. & Kohen, D. (1993) How ‘malignant$’ is the neuroleptic malignant syndrome? British Medical Journal. 307, 12231224.CrossRefGoogle ScholarPubMed
Gratz, S. S., Levinson, D. F. & Simpson, G. M. (1992) The treatment and management of the neuroleptic malignant syndrome. Neuropsychopharmacology-Biology-Psychiatry, 16, 425443.CrossRefGoogle ScholarPubMed
Katzung, B. G. (ed.) (1989) Basic and Clinical Pharmacology, pp. 264275, 338–339. Englewood Cliffs, NJ: Prentice Hall International(USA).Google Scholar
Walker, G. (1994) ABPI Data Sheet Compendium 1993–4, pp. 703706. London: Datapharm Publications.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.